Barclays PLC lifted its holdings in XOMA Co. (NASDAQ:XOMA – Free Report) by 300.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,256 shares of the biotechnology company’s stock after purchasing an additional 8,447 shares during the quarter. Barclays PLC owned 0.10% of XOMA worth $298,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of XOMA. BNP Paribas Financial Markets boosted its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the last quarter. Rhumbline Advisers grew its position in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC bought a new position in XOMA during the 3rd quarter worth $516,000. State Street Corp increased its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
XOMA has been the subject of a number of analyst reports. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Thursday, January 16th. HC Wainwright reiterated a “buy” rating and issued a $123.00 price target on shares of XOMA in a research note on Tuesday, January 7th.
Insider Transactions at XOMA
In other XOMA news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.
XOMA Trading Down 1.9 %
Shares of XOMA stock opened at $26.76 on Tuesday. The stock has a market cap of $315.23 million, a price-to-earnings ratio of -7.69 and a beta of 0.92. The stock has a 50-day moving average of $28.49 and a 200-day moving average of $28.07. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 1-year low of $18.57 and a 1-year high of $35.00.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Read More
- Five stocks we like better than XOMA
- What is a support level?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Upcoming IPO Stock Lockup Period, Explained
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Ride Out The Recession With These Dividend Kings
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.